Immunic needed support to expand its biotech business to Australia.

Immunic AG is headquartered in Germany from where overseeing an expansion to Australia to conduct clinical trials was daunting. We explain how Acclime supported Immunic’s Australia market entry.

Start reading

Client industry:
Life sciences
Services:
company registration
Country:
Germany

Immunic is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. Immunic AG in Germany wanted to expand to Australia and undertake clinical trials.

The challenge.

Immunic was interested in conducting clinical trials in Australia, but they needed support to manage this expansion and to administer an Australian subsidiary in line with local tax regulations and law. They also needed guidance to find key local partners to get their clinical trial up and running.

Acclime was recommended to us by several German biotech companies. We have been very pleased with how easy they have made it to estabish and administer our Australian subsidiary.

Immunic’s needs.

Advice on structuring and registration of the Australian entity
Completed company registrations with full compliance, licensing and transparency
Tax advice on investment incentives
Ongoing compliance and reporting support

Our solution.

With several recommendations from other German biotech companies, Immunic chose to partner with Acclime. Our team of tax, finance and compliance specialists made the whole process easy, with seamless support through the initial company incorporation process, to identifying key partners, to the ongoing management of Immunic’s Australian subsidiary.